# US 10,478,511 B2 · Therapeutic agent for tauopathy and method for screening thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,511 B2
- Document ID: US10478511B2
- Status: Granted
- Kind: B2
- Application number: 15/655,997
- Filed: 2017-07-21
- Published: 2017-11-09
- Granted: 2019-11-19
- Earliest claimed: 2014-10-22
- Assignees: National Center for Geriatrics and Gerontology
- Applicants: National Center for Geriatrics and Gerontology
- Inventors: Yuji Yoshiike
- Web page: https://patentgrep.com/patent/US10478511B2

## CPC

- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C09B 11/08: Phthaleins; {Phenolphthaleins; Fluorescein}
- C09B 57/00: Other synthetic dyes of known constitution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)

## Abstract

The present invention provides a tau protein aggregation inhibitor. In addition, a therapeutic agent or a preventive agent for tauopathy, including a tau protein aggregation inhibitor, and a method for screening for a tau protein aggregation inhibitor, are also provided. The problems are solved by a tau protein aggregation inhibitor including a fluorone dye or a pharmaceutically acceptable salt thereof. Moreover, the problems are also solved by a method for screening a tau protein aggregation inhibitor, wherein the method includes: (1) a step of preparing transgenic Drosophila that express a human tau protein in neurons, (2) a step of administering a candidate compound to the transgenic Drosophila, and (3) a step of measuring the motor function of the transgenic Drosophila that have been administered with the candidate compound in the step (2).

## Claims

### Claim 1

A method for inhibiting aggregation of tau proteins in Drosophila expressing human tau protein in neurons, comprising contacting the tau proteins with a fluorone dye or a pharmaceutically acceptable salt thereof, wherein aggregation of tau proteins is less in the presence of a fluorone dye as compared to tau aggregation in the absence of a fluorone dye.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the fluorone dye is rose bengal.